|
|
Newsroom 2005
- November 22, 2005
Neurochem enrolls first patient in Phase III clinical trial for Alzheimer's disease in Europe
Study on schedule
- November 17, 2005
Neurochem closes sale and leaseback transaction for Laval facilities
-
November 8, 2005
Neurochem announces sale and leaseback transaction for Laval facilities - sale price of C$32 million
-
November 8, 2005
Neurochem reports results for third quarter of fiscal 2005
-
November 7, 2005
Neurochem to report on third quarter of fiscal 2005
Neurochem will host a conference call Tuesday, November 8, 2005, at 4:30 P.M. ET
-
November 3, 2005
Neurochem to present at CIBC World Markets Sixteenth Annual Healthcare Conference
-
October 5, 2005
Neurochem receives third positive recommendation from Independent Safety Review Board to continue Phase III clinical trial for Alzhemed™
-
September 26, 2005
Neurochem to present at 2005 UBS Global Life Sciences Conference in New York City
-
September 13, 2005
Neurochem announces launch of European Phase III clinical trial on Alzhemed™ for treatment of Alzheimer's Disease
North American Phase III Clinical Trial on Alzhemed™ Fully Enrolled
-
August 22, 2005
Neurochem initiates submission of NDA with the U.S. FDA for Fibrillex™ in AA Amyloidosis.
-
August 10, 2005
Neurochem reports results for second quarter of fiscal 2005.
Neurochem will host a conference call Thursday, August 11, 2005, at 8:30 A.M. ET.
-
July 25, 2005
Neurochem Inc. announces exercise of warrant by Picchio Pharma Inc.
-
July 5, 2005
Neurochem completes patient recruitment for North American Phase III clinical trial for Alzhemed™
-
June 30, 2005
Neurochem announces FDA agrees to file and review NDA for Fibrillex™
-
June 13, 2005
Neurochem receives second positive recommendation from Independent Safety Review Board to continue Phase III clinical trial for Alzhemed™
-
June 9, 2005
New Fibrillex™ data presented at the meeting of the European League Against Rheumatism (EULAR).
-
June 5, 2005
New Fibrillex™ Data Presented at the European Renal Association-European Dialysis and Transplant Association Meeting.
-
May 19, 2005
Neurochem to present at UBS Global Pharmaceuticals Conference and at Fourth Annual Needham Biotechnology Conference.
-
May 12, 2005
At Annual and Special Meeting of Shareholders
Neurochem highlights the advancement of its drug development program as priority - issues first quarter results.
-
April 26, 2005
Neurochem receives positive recommendation from Independant Safety Review Board to continue phase III clinical trial for Alzhemed™.
-
April 18, 2005
Neurochem announces preliminary results of Phase II/III clinical study for Fibrillex™.
Plans meeting with FDA to present results.
-
April 8, 2005
Neurochem unblinds the Phase II/III Clinical Study for Fibrillex™ in the treatment of AA Amyloidosis.
-
March 31, 2005
Neurochem to present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference.
-
March 9, 2005
Neurochem Inc. completes public offering of 4 million common shares for gross proceeds of US$61.2 million.
-
March 4, 2005
Neurochem Inc. prices public offering of 4 million common shares for gross proceeds of US$ 61.2 million.
-
February 23, 2005
Neurochem Inc. files preliminary prospectus with Canadian and US Securities authorities for an offering of four million common shares.
-
February 22, 2005
Neurochem reports results for fourth quarter of fiscal 2004.
Neurochem will host a conference call Tuesday, Feb. 22, at 4:30 P.M. ET.
-
January 20, 2005
Francesco Bellini renews mandate for three-years as Chairman, President and CEO of Neurochem.
Neurochem Inc. announces senior management appointments and reassignment of responsibilities.
|
|
